Trafermin
Trafermin was approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on April 4, 2001. It was developed and marketed as Fiblast® by Kaken.
Trafermin is a recombinant human basic fibroblast growth factor (bFGF), which binds to FGF receptor and stimulates the proliferation of fibroblasts, epithelial cells, vascular smooth muscle cells and vascular endothelial cells. It is indicated for the treatment of patients with pressure sores and skin ulcers.
Fiblast® is available as spray for cutaneous use, containing 250 μg or 500 μg of Trafermin. It should be sprayed on ulcer surface once daily.
General Information
Update Date：2015-10-22
- Drug Name：
- Trafermin
- Research Code：
- KCB-1
- Trade Name：
- Fiblast®
- MOA：
- Promote the proliferation of fibroblasts and epithelial cells
- Indication：
- Pressure sore; Skin ulcer
- Status：
- Approved
- Company：
- Kaken (Originator)
- Sales：
- ATC Code：
Approved Countries or Area
Update Date：2015-09-07
| Approval Date | Approval Type | Trade Name | Indication | Dosage Form | Strength | Company | Review Classification |
|---|---|---|---|---|---|---|---|
| 2001-04-04 | First approval | Fiblast | Pressure sore, Skin ulcer | Spray | 250 μg; 500 μg | Kaken |
Biology Structure
Update Date：2015-09-25
| Type | Recombinant cytokines |
|
| Source | Human | |
| Molecular Formula | C764H1201N217O219S6 or C761H1196N216O218S6 | |
| Molecular Weight | 17122.7~17051.6 | |
| CAS No. | 131094-16-1 | |
| Expression System | E.coli |